Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Keith M. Olson"'
Autor:
Keith M. Olson, Andrea L. Devereaux, Payal Chatterjee, Savanah L. Saldaña-Shumaker, Amanda Shafer, Adam Plotkin, Ram Kandasamy, Alexander D. MacKerell, John R. Traynor, Christopher W. Cunningham
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: There is a major societal need for analgesics with less tolerance, dependence, and abuse liability. Preclinical rodent studies suggest that bifunctional ligands with both mu (MOPr) and delta (DOPr) opioid peptide receptor activity may p
Externí odkaz:
https://doaj.org/article/d66de2654cdc423f8f571b1ac7860458
Autor:
Wallace K. B. Chan, Keith M. Olson, Jesse W. Wotring, Jonathan Z. Sexton, Heather A. Carlson, John R. Traynor
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires treatments with rapid clinical translatability. Here we develop a multi-target and multi-ligand virtual screening method to identify FDA-app
Externí odkaz:
https://doaj.org/article/9d0a26fd74654609ba21d5d036893487
Publikováno v:
Frontiers in Chemistry, Vol 9 (2021)
Allosteric modulators (AMs) of G-protein coupled receptors (GPCRs) are desirable drug targets because they can produce fewer on-target side effects, improved selectivity, and better biological specificity (e.g., biased signaling or probe dependence)
Externí odkaz:
https://doaj.org/article/56b4d636375d43ff99dc8379bb8f75d3
Autor:
Lisa R. Gerak, David R. Maguire, Gerta Cami-Kobeci, Keith M. Olson, John R. Traynor, Stephen M. Husbands, Charles P. France, Lisette Acevedo, Barbara Belli, Peter Flynn
Publikováno v:
Behavioural pharmacology. 33(6)
Drugs targeting mu opioid receptors are the mainstay of clinical practice for treating moderate-to-severe pain. While they can offer excellent analgesia, their use can be limited by adverse effects, including constipation, respiratory depression, tol
Autor:
Alex Disney, Keith M. Olson, Amanda M. Shafer, Sierra C. Moore, Jessica P. Anand, John R. Traynor, Stephen M. Husbands
Publikováno v:
ACS Chemical Neuroscience. 13:3108-3117
The opioid crisis continues to claim many lives, with a particular issue being the ready availability and use (whether intentional or accidental) of fentanyl and fentanyl analogues. Fentanyl is both potent and longer-acting than naloxone, the standar
Publikováno v:
ACS Pharmacology & Translational Science. 5:694-709
G protein-coupled receptors (GPCRs) are highly druggable targets that adopt numerous conformations. A ligand's ability to stabilize specific conformation(s) of its cognate receptor determines its efficacy or ability to produce a biological response.
Autor:
Keith M. Olson, Todd M. Hillhouse, Gwendolyn E. Burgess, Joshua L. West, James E. Hallahan, Isaac J. Dripps, Allison G. Ladetto, Kenner C. Rice, Emily M. Jutkiewicz, John R. Traynor
Publikováno v:
J Pharmacol Exp Ther
Major depressive disorder is a highly common disorder, with a lifetime prevalence in the United States of approximately 21%. Traditional antidepressant treatments are limited by a delayed onset of action and minimal efficacy in some patients. Ketamin
Autor:
Natalie K. Barker, John M. Streicher, Attila Keresztes, Ryan Hecksel, Keith M. Olson, Marissa A. Lopez-Pier, Paul R. Langlais, Victor J. Hruby, John P. Konhilas, Paul L. Nguyen, Zekun Liu
Publikováno v:
Pain. 163:146-158
The opioid receptors are important regulators of pain, reward, and addiction. Limited evidence suggests the mu and delta opioid receptors form a heterodimer (MDOR), which may act as a negative feedback brake on opioid-induced analgesia. However, evid
Publikováno v:
The FASEB Journal
The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic requires treatments with rapid clinical translatability As such, several studies have screened FDA-approved drugs in silico at a limited number of classical antiviral s
Autor:
Lauren Rysztak, Keith M. Olson, Mehrnoosh Ostovar, James E. Hallahan, Peyton O. Koppenhaver, Stephen M. Husbands, Todd M. Hillhouse, John R. Traynor, Emily M. Jutkiewicz, Bryan F. Sears, Joshua L. West, Claire Meurice
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 378(3)
There are no Food and Drug Administration-approved medications for cocaine use disorder, including relapse. The mu-opioid receptor (MOPr) partial agonist buprenorphine, alone or in combination with naltrexone, has been shown to reduce cocaine positiv